1. MASTER Trial Inclusion Criteria
Prior MI
LVEF ≤ 30%
≥ 18 years of age

2. MASTER Trial Overview Enrollment (n=654)
Baseline Clinical Data, MTWA Testing, ICD Implant
35 w/o valid MTWA test
44 w/ other exclusion
Clinical follow-up every 6 months
(Minimum F/U 2 years)
Repeat MTWA testing every 12 months
Analysis cohort (n=575)

3. MTWA Testing Cambridge Heart CH2000 or Heartwave
Treadmill exercise recommended method
MTWA tests interpreted by Core Lab, blinded to patient characteristics and outcomes
Protocol required repeat testing of all MTWA indeterminates (unless medical justification supplied)
MTWA positive and indeterminate combined (“non-negative”) for primary outcome analysis 3

4. Baseline MTWA Classification68
293
214 4

5. Primary Endpoint Events
Negative
(n=214)
Non-neg
(n=361)
LTVTE
22 (10.3%)
48 (13.3%)
ICD Rx 20 43
SCD 2 5
LTVTE HR = 1.26, CI = , p = 0.37

6. MTWA and Total Mortality
Negative
(n=214)
Non-neg
(n=361)
Total mortality
13 (6%)
46 (13%)
Sudden cardiac
3 (23%)
7 (15%)
Non-sudden cardiac
5 (39%)
17 (37%)
Non-cardiac
15 (33%)
Unknown
2 (15%)
Total Mortality HR = 2.04, CI = , p = 0.02

7. Conclusions
In ICD treated patients with prior MI and LVEF ≤ 30%, LTVTE does not differ according to MTWA classification.
However, total mortality is higher in MTWA non-negative patients.

8. Study Implications
MTWA testing should not be used to withhold device therapy in MADIT-II indicated patients.
The biological explanation(s) for excess mortality in non-negative MTWA patients requires further study.